| Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8 L Yu, A Alva, H Su, P Dutt, E Freundt, S Welsh, EH Baehrecke, ... Science 304 (5676), 1500-1502, 2004 | 1549 | 2004 |
| Integrative clinical genomics of metastatic cancer DR Robinson, YM Wu, RJ Lonigro, P Vats, E Cobain, J Everett, X Cao, ... Nature 548 (7667), 297-303, 2017 | 795 | 2017 |
| Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination J Yu, MD Green, S Li, Y Sun, SN Journey, JE Choi, SM Rizvi, A Qin, ... Nature medicine 27 (1), 152-164, 2021 | 563 | 2021 |
| Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ... New England Journal of Medicine 385 (8), 683-694, 2021 | 523 | 2021 |
| Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer YM Wu, M Cieślik, RJ Lonigro, P Vats, MA Reimers, X Cao, Y Ning, ... Cell 173 (7), 1770-1782. e14, 2018 | 493 | 2018 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 441 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 399 | 2020 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 375 | 2022 |
| A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer … KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ... The Journal of urology 206 (1), 52-61, 2021 | 252 | 2021 |
| Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, ... Cancer 126 (18), 4156-4167, 2020 | 252 | 2020 |
| NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, MD Michaelson, L Nandagopal, JL Gore, S George, ... Journal of the National Comprehensive Cancer Network 17 (11), 1278-1285, 2019 | 211 | 2019 |
| A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, ... The Lancet 397 (10275), 695-703, 2021 | 205 | 2021 |
| NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ... Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020 | 204 | 2020 |
| Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a … KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ... JAMA oncology 4 (10), 1344-1351, 2018 | 204 | 2018 |
| Bladder cancer treatment response assessment in CT using radiomics with deep-learning KH Cha, L Hadjiiski, HP Chan, AZ Weizer, A Alva, RH Cohan, EM Caoili, ... Scientific reports 7 (1), 8738, 2017 | 202 | 2017 |
| Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response Y Zhang, SP Narayanan, R Mannan, G Raskind, X Wang, P Vats, F Su, ... Proceedings of the National Academy of Sciences 118 (24), e2103240118, 2021 | 175 | 2021 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 168 | 2022 |
| Rationale and design of the targeted agent and profiling utilization registry study PK Mangat, S Halabi, SS Bruinooge, E Garrett-Mayer, A Alva, ... JCO precision oncology 2, 1-14, 2018 | 167 | 2018 |
| Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches AM Udager, TY Liu, SL Skala, MJ Magers, AS McDaniel, DE Spratt, ... Annals of Oncology 27 (9), 1706-1712, 2016 | 140 | 2016 |
| Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors EF Cobain, YM Wu, P Vats, R Chugh, F Worden, DC Smith, SM Schuetze, ... JAMA oncology 7 (4), 525-533, 2021 | 136 | 2021 |
